HOME ·

HANSOH PHARMA

Going Global Weekly: Pharma Out-Licensing Deals Land in Succession as the A-Share Hong Kong Listing Pipeline Expands-20261023
Tags：
Going Global WeeklyHANSOH PHARMADSBJ
2026-10-23
HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October
Tags：
GENSCRIPT BIOASCENTAGEWUXI BIOHANSOH PHARMACSOP Hang Seng Biotech ETF
2026-10-20
HANSOH PHARMA (03692.HK): Signs ADC Strategic Collaboration and Licence with Roche; US$400mn Upfront, Over US$15bn Milestones
Tags：
NewTimeSpaceHANSOH PHARMA03692.HK
2026-10-19
HANSOH PHARMA (03692.HK): Refiles EU Marketing Application for Aumseqa
Tags：
HANSOH PHARMA03692.HKoverseas
2026-10-11
Hansoh(03692.HK): EU revokes Aumolertinib approval, EMA resubmission planned
Tags：
HANSOH PHARMA03692.HKdrug production registration approval
2026-09-27
HANSOH PHARMA (03692.HK): NMPA Accepts NDA for HS-20093, Its B7-H3-Targeting ADC, in Osteosarcoma
Tags：
NewTimeSpaceHANSOH PHARMA03692.HK
2026-09-24
HANSOH PHARMA (03692.HK): HS-20093 Gets Osteosarcoma Priority Review
Tags：
HANSOH PHARMA03692.HKPriority Review
2026-09-22
HANSOH PHARMA (03692.HK): HS-10374 meets co-primary endpoints in Phase III psoriasis trial
Tags：
HANSOH PHARMA03692.HKInnovative Drugs
2026-09-21
HANSOH PHARMA (03692.HK): Class 1 Innovative Drug HS-20197 for Injection Receives Clinical Trial Approval Notice, Intended for Advanced Solid Tumours
Tags：
HANSOH PHARMA03692.HKClass 1 Innovative Drug
2026-09-16
HANSOH PHARMA (03692.HK): Small Cell Lung Cancer Product HS-20093 Included in NMPA Priority Review Procedure
Tags：
HANSOH PHARMA03692.HKR&D Progress
2026-09-11
HANSOH PHARMA (03692.HK): NDA for HS-20093 in Small Cell Lung Cancer Accepted by NMPA
Tags：
HANSOH PHARMA03692.HKR&D Progress
2026-09-02
HK Stock Connect Daily Report: ZJ INNOLIGHT Officially Added to Stock Connect, Z.AI Surges Over 12%, Southbound Net Buying Reaches HKD 3.18 Billion - 20260827
Tags：
HK Stock Connect Daily ReportHANSOH PHARMAZ.AIPenghua CNI HK Equities Innovative Drugs ETFChina Universal CNI HK Equities Innovative Drugs ETF
2026-08-27
HANSOH PHARMA(03692.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 4.26 billion, YoY increase of 35.82%
Tags：
HANSOH PHARMA03692.HKprofit growth
2026-08-26
HANSOH PHARMA (03692.HK): Self-Developed Class 1 New Drug HS-10582 Tablet Receives NMPA Clinical Trial Approval Notice for Primary Hypercholesterolemia
Tags：
HANSOH PHARMA03692.HKClinical Trial
2026-08-06
Hansoh Pharmaceutical (03692.HK): HS-20093 Meets Primary Endpoint in Phase III Osteosarcoma Trial, to Advance NDA Filing
Tags：
HANSOH PHARMA03692.HK
2026-07-28
HANSOH PHARMA(03692.HK): NDA for HS-10568 Injection Accepted by NMPA for Secondary Hyperparathyroidism in Dialysis Patients
Tags：
HANSOH PHARMA03692.HKNew Drug Application
2026-06-10